FDA grants priority review to Eylea for diabetic retinopathy in patients with DME

The U.S. Food and Drug Administration has granted priority review for Eylea injection for the treatment of diabetic retinopathy in patients with diabetic macular edema, according to a Regeneron press release. In September, the U.S. Food and Drug Administration gave Eylea (aflibercept) intravitreal injection breakthrough therapy designation for the same indication.